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A 2-year rat feeding study with genetically modified NK603 maize sparked an international scientific and public
debate as well as policy responses by the European Commission. The European Food Safety Authority (EFSA)
evaluated the study as defective based on conceptual and methodological shortcomings by retroactive application
of the recommendations of its recent guidance on 90-day feeding studies. Our comparative analysis of the three
relevant NK603 publications, including a 90-day feeding study of Monsanto, showed that all of them satisfy or fail
to satisfy the EFSA evaluation criteria to a comparable extent; the rejection of only one of the papers is, thus, not
scientifically justified. We also show that EFSA's criteria are not standard practice in 21 other rat feeding studies
lasting at a minimum of 12 months. The review reveals critical double standards in the evaluation of feeding studies
submitted as proof of safety for regulatory approval to EFSA. We specifically argue that the current approach to
declare statistically significant differences between genetically modified organisms and its parents as ‘biologically
irrelevant’ based on additional reference controls lacks scientific rigor and legal justification in the European Union
(EU) system. Only recently, the EU authorities started building up an implementing system based on its own
legislation and supportive of the EU approach to risk assessment in the context of technology assessment. Until
these issues are resolved, we do not expect that neither the public nor the scientific debate will subside.
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Introduction
In 2007, Séralini et al. [1] re-analyzed the data of a 90-
day rat feeding trial conducted by Monsanto Company
and submitted to the European Food Safety Authority
(EFSA) to demonstrate the safety of their genetically
modified (GM) MON863 maize for food and feed im-
port in the European Union (EU). In their re-analysis,
the authors stated that the data generated by Monsanto
Company revealed signs of hepatorenal toxicity. The au-
thors concluded - in disagreement with Monsanto Com-
pany and EFSA - that ‘Longer experiments are essential
in order to indicate the real nature and extent of the
possible pathology.’ and that ‘With the present data, it
cannot be concluded that GM corn MON863 is a safe* Correspondence: hmeyer@ensser.org
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reproduction in any medium, provided the origproduct.’. This work sparked a controversial debate in
the public and in the political, regulatory, and scientific
communities regarding the disputed safety of that particular
GM crop and GM food and feed testing in general. The
controversy eventually elicited a policy response of the
European Commission's Directorate-General for Health
and Consumer Safety. In February 2013, an implementing
regulation on applications for authorization of GM food
and feed was adopted, which prescribes that for future GM
crop applications, 90-day feeding trials are mandatory [2].
Meanwhile, Séralini et al. [3] published a report about
a 2-year toxicology study with rats testing Monsanto's
NK603 glyphosate-tolerant GM maize and its Roundup
co-technology. The authors stated that female rats in the
treated group died earlier and more often than in the
control group. Treated female rats also developed mam-
mary tumours earlier and more often than control female
rats. Treated male rats showed higher levels of liver con-
gestion and necrosis as well as kidney nephropathies. Thehis is an open access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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rameters were kidney related. The Séralini study elicited
an immediate public debate showing a wide range of opin-
ions (which also precipitated in scientific journals, e.g.
[4-6]). As a reaction to this debate, the European Com-
mission decided to provide funding for an own 2-year
study on NK603 maize [7].
In this article, we evaluate the first response [8] by the
EU risk assessment body, EFSA, and the voiced criticism
that focuses on the underlying methodological issues. In
our analysis, we will leave out the critical issue of applied
statistical evaluations of the feeding trial, as this requires
other expertise.
EFSA [8] assessed the study [3] with regard to five cri-
teria: study objectives, study design, feed and treatment
formulation, statistical methods, and endpoint reporting.
These criteria are derived from the recently published
‘EFSA guidance on conducting repeated-dose 90-day
oral toxicity study in rodents on whole food/feed’ [9].
EFSA underlined in its accompanying press release that
their analysis focused on the methodology rather than
on the outcomes of the Séralini publication. EFSA con-
cludes that the study results are inadequately presented
with omission of key details of the design, conduct, ana-
lysis, and reporting. Due to its insufficient scientific
quality the study would be of no relevance for risk as-
sessments of neither glyphosate nor NK603 maize.
Due to the increasing scientific and public interest,
EFSA decided to make available all documents related to
the NK603 risk assessment and approval on the internet
[10,11]. Before, access to these documents was only pos-
sible upon individual request for information to EFSA.
This still holds true for all other approval applications of
other GM organisms (GMOs). Included in the NK603
dossier is the Monsanto Technical Report MSL-17555
[12] describing their 90-day rat feeding study and in-
cluding the raw data. For its second and final response,
EFSA [13] primarily added reactions of EU Member
States but did not expand or change the substantive is-
sues published previously.
In order to alleviate this result-triggered, selective ap-
plication of evaluation criteria and offer an objective
evaluation of the applied methodologies in other feeding
trials regardless of their outcomes, in particular those on
which EFSA based its safety conclusions, we carried out
a comparative analysis with the following objectives:
1. To evaluate how Monsanto's technical study [12]
and the subsequent peer-reviewed publication of
that study's data by Hammond et al. [14], as part of
the application for EU wide regulatory approval of
NK603 maize met the criteria EFSA applied so far
only to the Séralini et al. study [3]. We also include
the reply by Séralini et al. [15] on the voicedcriticism, which gives additional information on
study details.
2. To evaluate the degree of rigor and scrutiny EFSA
applied in its assessment of the Monsanto study [12]
and Hammond et al. [14] as elements of the NK603
risk assessment procedure. The two scientific
opinions of the EFSA Panel on Genetically Modified
Organisms on NK603 [16,17] serve as the basis for
our analysis.
3. To evaluate how 21 other long-term, peer-reviewed
rat feeding studies for comparable purposes but test-
ing other substances would fulfil EFSA's criteria.
These additional studies were selected for their
methodological criteria being similar to the Séralini
study, e.g. a duration of 12 months or longer, using
SD rats and performing toxicology sometimes in
combination with carcinogenicity tests.
Comparative analysis of the application of the EFSA criteria
The three NK603 publications discussed by us were
written - and hence, experiments were planned - before
EFSA published its 2011 Guidance on 90-day feeding tri-
als. While the retrospective application of new standards
(i.e. study methods) as undertaken by EFSA [8] is debat-
able, it is broadly accepted that risk assessment inform-
ing regulatory decision-making should be based on the
latest state of knowledge and standards. A re-evaluation
of the applied methods of relevant, older studies is justi-
fied if applied to all such relevant studies - but meaning-
less or even counterproductive when applied selectively
to one study or a subset of studies only triggered by
their reported (here adverse) effects. We consider such a
selective re-evaluation as inappropriate. We note that
the main responsibility for EFSA's recent work lies with
the European Commission that in its mandate to EFSA
singles out the Séralini study for review [17].
EFSA criterion: study objectives
EFSA [8] notes with regard to Séralini et al. [3] that the
‘study objectives are unclear’. EFSA further clarifies that
‘If a specific guideline is chosen and followed, then the
objectives are inherently defined in the guideline.’ To
clarify what ‘inherently defined’ objectives entail, we ana-
lyzed the four Guidelines of the Organization for Eco-
nomic Co-operation and Development [18-21] discussed
in this context (OECD nos. 408, 451, 452, 453, respect-
ively). While the three latter Guidelines revised in 2009
give clear objectives, Guideline 408 on 90-day oral tox-
icity originally adopted in 1981 and revised in 1998 lacks
such clarity. Guideline 408 is the guideline of choice by
Monsanto Company for their 90-day rat feeding trial.
Open issue according to EFSA: ‘The study objectives
need to be clearly stated a priori in the study protocol.’
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Organization for Economic Co-operation and Develop-
ment (OECD) was followed by some manufacturers for
GMOs even if it was not designed for that purpose. We
have explored more parameters and more frequently
than recommended in this standard in a long-term ex-
periment.’ The authors explained that they added bio-
chemical and haematological measurements using 10
rats per group as described in the OECD Guideline 453.
This apparent combination of elements of two OECD
guidelines and the addition of more parameters did not
qualify as proper description of the objectives of the
work by EFSA.
In its technical 90-day study, Monsanto tested a low-
dose group (LD 11% NK603) and a high-dose group
(HD 33% NK603) versus two parental control groups
and six non-parental, so-called reference controls for
13 weeks. Blood and urine biochemical parameters,
amongst others, were measured at an interim time point
after 4 weeks and at termination of the study. The state-
ments by Monsanto [12] and later by Hammond et al.
[14] to have adapted the OECD Guideline 408 were con-
sidered by EFSA to be sufficient. Neither the nature nor
the consequences of the adaptations made to the re-
quirements of OECD Guideline 408 were explained in
these two publications or in the scientific opinions of
EFSA Panel on Genetically Modified Organisms [16,17].
Since OECD Guideline 408 [18] in contrast to the
more recent OECD guidelines does not provide clear ob-
jectives, it is doubtful whether a mere reference to this
guideline as provided by Monsanto suffices EFSA's new
standards on study objectives. We conclude that regard-
ing this criterion, the Séralini publication provides at
least the same quality in terms of clarity and explanation
as the Monsanto and Hammond studies.
EFSA criterion: study design
The study design applied by Séralini et al. [3] triggered
two main criticisms by many commentators including
EFSA [8]: (a) the number of rats per group and (b) the
choice of the strain of rats.
A. EFSA [8] states: ‘[g]iven that Séralini et al. (2012)
conducted a two-year study, it is unclear why an
OECD guideline suitable for a 2-year chronic tox-
icity or carcinogenicity study (i.e. OECD 451, OECD
452, or OECD 453) was not adhered to.’ Séralini
et al. [3] used 10 rats per group as recommended by
OECD Guideline 453 [19] for the chronic toxicity
phase. But OECD Guideline 453 also clearly states
that this lower number is only justified when a car-
cinogenicity phase with 50 rats per group is run in
parallel to support the interpretation of the toxicity
data. Later, Séralini et al. [15] argued that the OECDGuideline 452 in its 1981 version [22], which was
applicable for the 2-year toxicology study conducted
from 2008 to 2010, advised to only use 10 rats out
of the 20 per group for blood and urine sampling
and analysis. The recommendation to use at least 10
rats per group for biochemistry analysis at the
chosen time points is maintained in the current ver-
sion of Guideline 452.
Monsanto [12] used 20 rats per sex and group, while
the actual values for blood chemistry, haematology
and qualitative, and quantitative urine analyses were
based on samples from 10 rats per sex and group,
thus, comparable to the approach of Séralini et al.
[3]. Nowhere in the two versions of Guideline 452
or in the Monsanto study, a method for how to
select the 10 animals out of the 20 animals per
group for the biochemistry tests is specified.
B. Regarding the choice of SD rats, EFSA notes that
this “strain of rats chosen is known to be prone to
development of tumours over their life […] This is
neither taken into account nor discussed in the
Séralini et al. (2012) publication.” A discussion on
the choice of rats with regard to their tendency to
develop tumours is not relevant for 90-day studies.
Nevertheless, EFSA recommends stating reasons for
the choice of the strain in its new guidance on 90-
day feeding trials.
Open issue according to EFSA: ‘The biological
relevance of the rat strain used should be justified with
respect to the design choices.’
Neither Séralini et al. [3] justify the choice of SD rats
nor do Hammond et al. [14]. Monsanto [12] explains
that ‘[t]he rat was selected for the study since this spe-
cies has been traditionally used to assess the safety and
wholesomeness of food.’ This pragmatic explanation un-
derlines the customary use of SD rats in such trials
which of course extends also to the Séralini study but
does not give a scientifically sound justification for its
use with regard to the design choice as implied by
EFSA's wording [8].
In (Additional file 1: Table S1), we present information
on the actual use of SD rats in peer-reviewed, long-term
studies and the types of information researchers usually
provide and scientific journals require on the choice of
animals. According to the information available, SD rats
were chosen as standard test organisms by the two lar-
gest toxicity/carcinogenicity research projects worldwide
and at least 21 long-term studies:
1. The National Toxicology Program of the US
Department of Health and Human Services uses this
strain in its 2-year studies, after in-depth discussions
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previously used strains [23].
2. The European Ramazzini Foundation for Oncology
and Environmental Sciences (Italy) uses SD rats in
its Ramazzini Foundation Cancer Program since
more than 40 years [24].
Contrary to many media reports based to a large ex-
tent on scientists' personal opinions posted by the
Science Media Centre [25], SD rats are used routinely in
long-term toxicology and carcinogenicity studies. The
rational to do so is that (additional) carcinogenic effects
of test substances can be detected more effectively in
rats that develop tumours at a relevant rate within the
time span of a 2-year trial. Actually, the prime issue of
an informed debate would not be so much the choice of
the strain of rats but the choice of the numbers of rats
depending on the strain used. The OECD Guideline 116
[26] on the conduct of long-term carcinogenicity studies
states that ‘[f]or strains with poor survival such as Spra-
gue–Dawley rats, higher numbers of animals per group
may be needed in order to maximize the duration of
treatment (typically at least 65/sex/group).’ The US Food
and Drug Administration (US FDA) [27] recommends
for carcinogenicity tests with strains with known prob-
lems in survivorship that the researchers need to ensure
that at least 25 rats from those used initially remain alive
at the end of the 2-year trial. For long-term toxicity trials
as conducted by Séralini et al. [3], no specific recom-
mendations are given by the US FDA. With regard to
the recommended number of 10 rats per toxicological
test in OECD Guideline 452 [20], the above recom-
mendation of FDA should be applied to ensure that
in average, more than 10 rats would be available for
terminal testing. The reported survival rates of the
control rats in Séralini et al. [3] (70% for males, 80% for fe-
males) lie at or above the upper range presented in avail-
able literature on survival rates of SD rats in 2-year
studies [28-31].
We conclude that with regard to the choice of rats,
a pragmatic approach was followed by Monsanto,
Hammond et al. [14] and also Séralini et al. [3]. Since the
Séralini group had set out to repeat the 90-day feeding
trial by Monsanto but to differ with regard to the ex-
tended testing time and parameters measured, the choice
of rat was appropriate in order to allow for comparability
with regard to this factor. We also conclude that the
SD rat strain used is a standard organism for toxicity
and carcinogenicity tests. A rejection of the validity of
the Séralini study based on the choice of rats would
therefore either be based on a lack of familiarity with
the scientific field. Or these criteria would have to
apply to all carcinogenicity trials conducted to date with
this rat strain and, thus, leave us with hardly any validcarcinogenicity study. Criticism of the Séralini study
based on the lack of a scientific explanation of the choice
of the rat strain would similarly apply to the Monsanto
and Hammond publications.
Open issue according to EFSA: ‘Suitable controls for
all treatment groups are not present.’
None of the discussed OECD guidelines was developed
for the testing of whole foods but rather for testing the
toxicity of isolated chemicals when feeding rats with
standardized, nutritionally balanced feed. In most cases,
the test substance is administered separately from the
normal feed or mixed with the feed in a minor volume.
As long as the addition of the test substance to the feed
does not alter significantly the relative concentration of
the feed components, a single control with zero test sub-
stance is sufficient. If the test substance is an inherent
component of the feed as in the NK603 feeding trial and
the different test concentrations are produced through
varying percentages of GM and non-GM maize varieties
in the feed, appropriate controls are necessary according
to EFSA [9]. Hammond et al. [14] and Monsanto [12]
report that all test groups received feed containing 33%
maize with a different percentage of GM versus non-
GM maize. Séralini et al. [3] did not report whether they
had adjusted the total maize content to 33% in those
batches containing 11% or 22% GM maize. To clarify,
Séralini et al. [15] informed that all feed batches were
mixed to contain 33% maize in total.
We conclude that based on the information given by
Séralini et al. [15], this open issue is closed.
Open issue according to EFSA: ‘Measures taken to
reduce the risk of bias (e.g. blinding) are not reported.’
While EFSA [8] has noted that Séralini et al. [3] did
not report on measures taken to reduce bias in their ex-
periments, we note that also neither Hammond et al.
[14] nor Monsanto [12] reported such measures. Blind-
ing measures are not requested by any of the above-
mentioned OECD guidelines. However, Séralini et al.
[15] explained that anatomopathology and biochemical
measures were indeed performed in a blinded manner.
The issue of blinded evaluation was promoted by
EFSA when it presented its draft [32] of the above-
mentioned Guidance on a 90-day oral toxicity study for
public consultation. EFSA's approach was rejected by
many commentators from pathology sciences and indus-
try [33] with reference to the ‘Best Practices Guideline:
Toxicologic Histopathology’ of the Society of Toxicologic
Pathology [33]. This guideline explains that unblinded
evaluation is regarded as the appropriate approach in
the first round of pathological observations because it
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logic evaluation and to find important, and sometimes
subtle, differences between the tissues of treated and un-
treated animals’. The guideline recommends that blinded
evaluations should be applied in the re-evaluation of
findings in specific tissues and when samples with a de-
fined spectrum of lesions due to a known toxic syn-
drome are investigated. These recommendations to not
apply blinding as a general measure were reflected in
EFSA's report on their public consultations [34] and in
the final EFSA Guidance on 90-day oral toxicity study. It
is unclear why EFSA [8] requested blinding measures in
the context of the Séralini study but did take no issue of
this in its positive opinions on the NK603 dossiers in-
cluding Monsanto's rat feeding studies.
We conclude that a double standard was applied with
regard to the criterion of blinding. We also conclude
that EFSA’s approach does not reflect the previously
published opinions of various experts in the field.
EFSA criterion: feed and treatment formulation
Open issue according to EFSA: ‘The appropriateness
and comparability of the diets cannot be assessed as
critical information about their composition is not
reported.’
Séralini et al. [3] did not present their data on the
composition of the feed but informed that ‘all feed for-
mulations consisted in balanced diets, chemically mea-
sured as substantially equivalent except for the transgene’.
Similarly, Hammond et al. [14] did not present such
data but mentioned that all diet preparations were an-
alyzed to confirm that they met the supplier's specifi-
cations for certified 5002 rodent diet. Monsanto [12]
presented detailed data on the composition of the feed, as
it is standard procedure for technical studies for regulatory
feeding trials.
We conclude that the two publications by the Hammond
and Séralini groups do not fully comply with this criterion
while both studies mention that the composition of the
different feed was measured and found to be comparable.
A rejection of only one study due to the lack of reporting
of data would constitute a double standard.
Open issue according to EFSA: ‘The stability of the
diets cannot be assessed as details of their storage
conditions are not provided.’
EFSA [8] noted that Séralini et al. [3] did not inform
about the storage conditions of the feed - likewise, nei-
ther Hammond et al. [14] nor Monsanto [12] informed
about this. Consequently, the stability of the diets cannot
be assessed in any of the studies submitted by thedevelopers to EFSA, which went uncommented in EFSA’s
positive opinions on NK603 maize [16,35].
Open issue according to EFSA: ‘It is impossible to
evaluate whether or not there was any contamination
of the diets, e.g. by mycotoxins, as it is not reported.’
Although Séralini et al. [3] did not report about myco-
toxin measurements in their original publication, later,
the authors [15] stated that all measured mycotoxins
showed concentrations below the recommended thresh-
old values for food and feed. The EU maximum level is
4 ppb for e.g. the sum of Aflatoxines B1, B2, G1, and G2
in processed maize for human consumption and 20 ppb
or lower for Aflatoxine B1 in feed materials. Similarly,
Hammond et al. [14] informed that the levels of afla-
toxins were below detection limits but did not provide
the actual individual measurements or raw data. Monsanto
[12] did not refer to aflatoxins alone but to the meas-
urement of a total of 19 different mycotoxins. The author
noted that there was no contamination with myco-
toxins that might interfere with the results. Of the 19
analyzed mycotoxins, 4 (Deoxynivalenol, Fumonisin B1,
B2, B3) could be detected in individual concentrations
up 1.6 ppm in the various maize samples. The concen-
tration did not exceed 3 ppm in the formulated diet,
which Monsanto [12] regards as the No Observed Effect
Level for Fumonisin B1 in rats according to Voss et al.
[36]. The EU maximum level for Fumonisin B1 and B2 lies
at 60 ppm for maize as feed material while the EU max-
imum level for maize products for human consumption is
1 ppm or lower.
Open issue according to EFSA: ‘The amount of
residues of glyphosate and its metabolites in treated
maize NK603 is not reported.’
Séralini et al. [3] did not present the results of their
glyphosate measurements but stated that pesticide con-
tent did not exceed standard limits. The current EU
maximum residue level for glyphosate in maize is
1 ppm. Hammond et al. [14] noted that the levels of gly-
phosate were below detection limits but also did not give
any data. In contrast, Monsanto [12] informed that gly-
phosate was indeed measurable: ‘Glyphosate residue in
the test grain (0.09 ppm) was slightly above the analyt-
ical detection limit of 0.05 ppm.’ It is very likely that
the NK603 maize used as feed was treated with a
glyphosate-containing herbicide during its growth. In
order to address the presence of two factors relevant for
risk assessment - the transgene and the complementarily
used herbicide - information on the use of glyphosate
and its residues should be presented in research relevant
for risk assessment [37].
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GMO, GMO + R, and R cannot be evaluated since
the food and water intakes of the GM- and
R-treated groups, respectively, are not clearly
reported.’
Séralini et al. [3] did not present the values of feed and
water intakes (both containing the test substances) - but
also Hammond et al. [14] did not present feed intake
data (only feed contained the test substance). Monsanto
[12] presented feed intake data, as this is standard pro-
cedure for technical studies for regulatory feeding trials.
However, this data still cannot be used to quantify the
exposure to the CP4 EPSPS protein because Monsanto
[12] did not quantify the concentration of CP4 EPSPS
protein in the maize kernels used to mix into the feed.
Monsanto [12] only conducted qualitative ELISA tests to
confirm the presence or absence of the CP4 EPSPS pro-
tein. The impossibility to calculate exposure data based
on the information given by Monsanto [12] was not
flagged by EFSA in its two positive opinions on the
NK603 dossier.
While the presentation of data on concentrations of
contaminants is certainly useful, a rejection of the valid-
ity of the Séralini study based on the fact that only state-
ments on such concentrations are given is debatable.
And again, we conclude that applying a criterion to only
one study would constitute a double standard in all four
open issues discussed above.
EFSA criterion: endpoint reporting
Open issue according to EFSA: ‘All collected endpoints
should be reported openly and transparently.’
The reporting on endpoint data is an essential feature
of regulatory studies. Monsanto [12] delivers all data as
is required for such regulatory studies amounting to
1,180 pages supplementary information, most of them
containing raw data. Obviously, such amount of data
is unpublishable in any scientific journal. Therefore,
Hammond et al. [14] provide means and standard devia-
tions only and did not present the urine chemistry values.
Séralini et al. [3] did not present comparable means and
standard deviations summarizing the raw data, but more
complex statistical evaluations of some selected data sets.
Séralini et al. [15] announced that more data would be
published in following publications.
The tenth open issue listed by EFSA actually shows a
profound difference between the Séralini study and the
two others. We conclude that the approach of the Séralini
study deviates from general practice with regard to the
reporting of results of such feeding studies; more informa-
tion should be made available.Conclusions of the comparison of three feeding trials
testing NK603 maize
Our analyses as summarized in Table 1 revealed that
the major difference between the studies of the French
group and Monsanto lies in the presentation of the
endpoint data, one of the contentious issues also in
the public scientific debate. In January 2013, the French
group has deposited their raw data at a notary and will
give access to them if Monsanto's raw data on NK603
and glyphosate safety are accessible publically as well
[38]. Shortly after this announcement, EFSA has en-
abled open access to the NK603 files at its web page
[11]. Unfortunately, data on safety tests with glyphosate
remain confidential, as it is the general rule for pesti-
cide data.
For all other methodological criteria established by
EFSA, we only found differences between the two
peer-reviewed publications that did not exceed the
normal range of differences exhibited by all published
experiments that study a similar issue with similar
protocols, including those considered for regulatory
purposes. As expected and required, Monsanto's tech-
nical study presents more details than the two publications.
These standards cannot be met by scientific publica-
tions as journals do not allow for publications exceeding
several hundreds of pages of technical details. However,
even in this extensive technical study, a whole range of
criteria requested and applied by EFSA to the Séralini
study and deplored as insufficient, were likewise absent
or incomplete.
In conclusion, we note that applying the evaluation cri-
teria to Séralini et al. [3] only but not to Monsanto [12]
and Hammond et al. [14] constitutes a double standard.
Comparative analysis of other long-term rat feeding studies
In a literature search effort, we found 21 peer-reviewed
long-term studies with SD rats published in the last 20 years
(Belpoggi et al. [39]; Bornhard et al. [40]; Butenhoff et al.
[41]; Gámez et al. [42]; Gutiérrez et al. [43]; Hack et al. [44];
Holmberg and Eckstöm [45]; Johannsen and Levinskas
[46]; Klimisch et al. [47]; Lee et al. [48]; Liang et al. [49];
Minardi et al. [50]; Morcos and Camilo [51]; Perricone
et al. [52]; Perri et al. [53]; Quast [54]; Soffritti et al. [55];
Soffritti et al. [56]; Soffritti et al. [57]; Soffritti et al. [58];
Voss et al. [59]). The aim of our analysis of these studies
was to find out whether the set of EFSA criteria with its
10 requirements is met by generally applied standards
in scientific toxicology and carcinogenesis research. Our
compilation revealed that the EFSA criteria and require-
ments applied to the Séralini study are hardly fulfilled by
any of these publications (for details, see Additional file 1:
Table S1). The only requirement that is consistently ful-
filled by the 21 peer-reviewed publications is the endpoint
reporting in the form of means and standard deviations.
Table 1 Compliance with the EFSA requirements by the three studies
Requirement Level of compliance
Séralini et al. [3] Hammond et al. [14] Monsanto [12]
Study objectives need to be clearly stated a priori in the study protocol Medium Medium Medium
Suitable controls for all treatment groups need to be presented No data shown (high)a High High
Biological relevance of the rat strain used should be justified Low Low Low
Measures taken to reduce the risk of bias (e.g. blinding) need to be taken No data shown (high)a No data shown No data shown
Critical information about the diet composition need to be reported No data shown No data shown High
Details of the storage conditions of the feed need to be provided No data shown No data shown No data shown
Contamination of the diets, e.g. by mycotoxins, pesticides etc., need to
be reported
No data shown (medium)a No data shown High
All collected endpoints should be reported openly and transparently No data shown Medium High
The presented data need to ensure the calculation of exposure to the
test substance
No data shown No data shown Medium
The sample size (power) calculation must be presented, especially when






Based on EFSA [8] and EFSA Scientific Committee [9]. aCompliance level is enclosed in brackets based on additional information given by Séralini et al. [15].
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few studies. Only one publication mentioned the OECD
guideline the researchers adhered to in their experi-
ments [42]. The choice of the strain was never discussed
in scientific publications as required by EFSA. Only
Butenhoff et al. [41] deliberated on the characteristics of
SD rats in the context of comparing their results with
studies using other strains. Only Liang et al. [49] applied
a blinded evaluation in their histological analysis as
asked for by EFSA. Butenhoff et al. [41] had chosen a
blinded evaluation for their re-assessment of existing
histopathological probes. None of the 21 studies re-
ported about storage conditions or presented power
calculations.
An interesting point with regard to the scientific and
public discourse is the number of rats used in these
peer-reviewed experiments. While public and scientific
commentators, including EFSA [9], obviously assume
that all animals tested per group and sex are in the end
also used for analysis of e.g. biochemical parameters, the
applicable OECD guidelines and several of the screened
publications apply a different approach. As mentioned
previously, the OECD Guideline 452 recommends the
use of 10 out of the 20 rats per group for biochemical
analysis. As indicated in (Additional file 1: Table S1) 9 of
the 12 publications that analyzed biochemical parame-
ters in the toxicology study also used 10 or fewer rats in
some or all tests.
EFSA reactions regarding the three NK603 studies
Monsanto [12] reported 77 comparisons in which statis-
tically significant differences between the NK603 treat-
ments and the different controls were measured (fordetails, see Additional file 2: Table S2). The authors con-
sidered 71% (55) of the statistically significant differences
between treatments and controls as either ‘not biologic-
ally significant’ (19), ‘not biologically relevant’ (28), ‘not
biologically meaningful’ (6), or ‘not toxicologically sig-
nificant’ (2). Seventeen of the remaining 22 comparisons
showed a significantly higher food consumption of the
HD 33% NK603 maize group. Monsanto [12] noted that
‘[i]n total, some 1,050 comparisons were made and ap-
proximately 53 of these were anticipated to be signifi-
cant by chance alone at the 5% significance level.’ It
remains unclear if the author intended to suggest that
these remaining 22 significant differences were produced
by mere chance and, thus, could also be regarded as ir-
relevant. The author's decisions are based on conceptual
and methodological arguments, no peer-reviewed sci-
ence is provided to underpin the argumentation and
categorization.
In its first opinion - based on Monsanto [12] - EFSA
[35] did neither report about the 77 statistically signifi-
cant differences nor about the explanations of Monsanto
and the underlying norms and standards to declare 55 of
them as irrelevant. In fact, no agreed EU norms and
standards existed in 2003 that EFSA could have used
to justify such a categorization. EFSA also did not
comment on the remaining 22 comparisons that Mon-
santo did not declare explicitly as insignificant but did
so implicitly by assigning them to pure chance only and,
thus, did forego any further analysis as to their quality.
EFSA declared that only two comparisons - average cor-
puscular volume and average corpuscular haemoglobin
in female rats in the high-dose group - exhibiting
‘slightly elevated levels’ showed ‘consistent differences’
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differing comparisons out of 77 significant differences
were singled out and much more pronounced differ-
ences recorded, for example, in the group of haematol-
ogy values went uncommented by EFSA.
In its second opinion, EFSA [16] based its essentially
unchanged conclusions on Hammond et al. [14]. This is
surprising because the authors state explicitly that there
are no statistically significant differences anymore. The
reason for this complete loss of the statistical significant
differences still reported by Monsanto [12] is due to a
new approach of dealing with the raw data. In contrast
to Monsanto [12], two modifications were applied: (1)
the only comparator in Hammond et al. [14] are the
mean values of all six reference controls but not of the
parental control and, (2) additionally, the double stand-
ard deviation is used as upper and lower threshold to
determine the statistical significance. This new statistical
approach - uncommented by EFSA - resulted in eliminat-
ing all statistically significant differences as still reported by
Monsanto [12]. No scientifically documented justification
for this approach to eliminate statistical differences was
provided by Monsanto nor requested by EFSA.
In conclusion, with regard to the provisions of the EU
laws on GM organism risk assessment and approval, we
argue that a comparison of a GM plant only to genetic-
ally unrelated reference controls excluding the unmodi-
fied isogenic parents is not in compliance with EU law
and guidelines on GMO risk assessment. Based on the
above reported outcomes of our comparative analysis,Table 2 Comparison of EFSA's scientific opinions on Monsant
Safety of the whole GM food/feeda T




No consistent differences in the measured clinical, biochemical, and
histological parameters were noted for rats fed on non-GM or NK603
maize, except for slightly elevated levels of average corpuscular volume






Since both parameters were calculated from other data (hematocrit/red
blood cells and haemoglobin concentration/red blood cells, respectively),
and no other observations of treatment-related effects were made, the
applicant suggests that an artifactual difference resulted from a slightly
higher hematocrit or haemoglobin concentration and slightly lower red












The Panel accepts this as a reasonable interpretation of the data. The
Panel also found the doses chosen for the study (11% or 33% of diet)
appropriate, as they did not distort the nutritional balance of the
experimental animals. The standard rodent diet used by the test






aEFSA Panel on Genetically Modified Organisms [35], p.9; bEFSA Panel on Geneticallwe note a striking double standard in rigor applied in
the evaluation of the submitted rat feeding trials con-
ducted and submitted by the developer to EFSA in com-
parison to the rigor applied in the evaluation of the
Séralini study.
The need for appropriate regulatory sciences
Of prime importance and long overdue is an inclusive
discussion on the appropriate testable, scientific hypoth-
eses and methodologies that are supportive of the provi-
sions and tasks formulated by the EU legal framework
on risk assessment of GM organisms. The EU law is
based on the axiom that risks, which may be caused by
GM organisms, cannot be a priori-deducted from ex-
perience with existing organisms. Due to their genomic
and evolutionary novelty, specific laws regulate the test-
ing in the open environment and the market approval
process of GM organisms since 1990. Therefore, the EU
Directive 2001/18 on the deliberate release into the en-
vironment of genetically modified organisms clearly
states as a ‘General Principle’ for environmental risk as-
sessment that ‘identified characteristics of the GMO and
its use which have the potential to cause adverse effects
should be compared to those presented by the non-
modified organism from which it is derived and its use
under corresponding situations’. Nowhere does this
Directive or the Regulation (EC) No 1829/2003 on gen-
etically modified food and feed suggest that GM organ-
isms also need to be compared to unrelated control
organisms in the context of risk assessment (see Regulationo's rat feeding study with NK603 maize
oxicological assessment of the whole GM food/feedb
published 90-day study in rats fed either maize NK603 as 11% or 33%
f the diet, or a diet which to 11% or 33% was made up of non-GM
aize grain having a comparable genetic background to maize NK603
LH82 x B73), resulted in
o consistent differences in the measured clinical, biochemical, and
istological parameters, except for slightly elevated levels of average
orpuscular volume and average corpuscular haemoglobin in female rats
dministered the high dose (Hammond et al., 2004).
ince both parameters are calculated (hematocrit/red blood cells and
aemoglobin concentration/red blood cells, respectively), and no other
bservations of treatment-related effects were made, the applicant
uggested that these statistical differences were artefacts resulting from a
lightly higher hematocrit or haemoglobin concentration and slightly
ower red blood cell count at this sampling.
urthermore, it was pointed out that the observed difference in average
orpuscular volume and average corpuscular haemoglobin had no
iological relevance.
he EFSA GMO Panel finds the interpretation of the data acceptable. The
FSA GMO Panel also found the doses chosen for the study (11% or 33%
f diet) appropriate, as they did not distort the nutritional balance of the
xperimental animals. The standard rodent diet used by the test
aboratory contains approximately 33% maize grain.
y Modified Organisms [16], p.16-17.
Table 3 Information on relevance of reference varieties
used by Monsanto [12] for the US corn production
Reference variety Summary of internet searcha
Campbells 6995 No relevant information available
Cropplan Genetics 461 No relevant information available
Crows 363 No relevant information available
DK537 Indication of use ten and more years ago
Parental line of Yield Gard rootworm corn
Dekalb DKC53-29
DK539 Indication of use ten and more years ago
Described as ‘widely adapted’ by Dekalb
in 1999
Pioneer 3394 Highly successful corn variety until 1995,
dominating the US corn belt
After causing high economic losses in 95/96
due to very low resistance to Gray leaf spot
fungi, the planting of this variety ceased
aInternet search was performed on 12 December 2012 with Google and key
words < ‘name’ AND corn > as well as < ‘name’ AND corn AND acreage >.
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http://www.enveurope.com/content/25/1/331829/2003 Art. 4 1. and Art. 5 3. (e)). The evaluation of
characteristics of a GM organism with regard to the ‘ac-
cepted limits of natural variations’ - requiring data from un-
related reference varieties - is only mentioned in Art. 5 3.
(f) in the context of labelling but not risk assessment.
We argue that the concept of substantial equivalence
or the concept of familiarity, originally developed in the
context of the US regulatory system for GM organisms
and based on opposite assumptions as the EU regulatory
system [60], is not per se applicable in the EU context.
One element of this US approach is the additional use of
unrelated varieties as reference controls to establish the
natural variation against which GM food products need
to be evaluated. While this approach was taken up in
a report by the World Health Organisation [61] and
in a technical risk assessment guidelines of the Codex
Alimentarius Commission [62], it failed to become recog-
nized in the more general Codex Alimentarius Commis-
sion Principles 44–2003 [63] or in the international legally
binding Cartagena Protocol on Biosafety [64]. In practice,
adding genetically unrelated controls will increase the un-
specific background variability in the data and make the
statistical detection of specific differences due to the inser-
tion of the transgenic trait more difficult or impossible.
We conclude that the actual effect of introducing the
use of unrelated reference controls lies more in provid-
ing an instrument to declare technology-induced signifi-
cant differences as irrelevant against the background of
unspecified ‘noise’ (stemming from broad, unrelated nat-
ural variation) than in setting up a sound methodology
for risk assessment under the applicable legal frame-
work. While over the past years, no norms, standards,
and scientific criteria for the concept of familiarity and
its core instrument of reference controls were developed,
it is still at the discretion of applicants and authorities if
and how to use the respective test results.
The non-scientific character of this approach can be il-
lustrated through its use by Monsanto [12]. Monsanto
selected six maize varieties as reference controls ‘se-
lected to represent a range of growing environments and
a diversity of germplasm’. Monsanto does not prove that
the selected varieties and the growing areas are indeed
representative for the USA maize production and subse-
quent exposure of animals and humans to maize prod-
ucts. Such demonstrated representativeness would be
essential to justify the use of reference control as means
to declare biological irrelevance in regulatory science, as
for example suggested by the Codex Alimentarius Com-
mission guidelines [62]. EFSA accepted the approach by
Monsanto [12] without requiring proof for representa-
tiveness or any other robust scientific justification of
the use of these reference controls. In order to obtain
some information about the six varieties, we performed
an internet search. As shown in Table 3, no relevantinformation could be found for three of the used var-
ieties. Two of them obviously had some level of import-
ance ten or more years ago. Only for Pioneer 3394
maize, we were able to retrieve information that showed
high relevance of this variety for the US maize agricul-
ture in the 1990s. Based on this search, we conclude that
it is doubtful whether the chosen six varieties were a
representative sample for the US maize when the Mon-
santo rat study was performed. In any case, it can safely
be concluded that the six varieties were of no relevance
for EU maize agriculture when EFSA accepted the study
in 2003 and 2009. Biological irrelevance of many statisti-
cally significant differences between NK603 maize and
its unmodified parents was declared without any scien-
tific justification or experimental proof.
Conclusions
The recent controversy focused on the validity of the
study published by Séralini et al. [3] as adequate evi-
dence for questioning the safety of NK603 maize and its
glyphosate-based co-technology. In our comparative
analysis based on four out of five criteria of EFSA, we
found the studies of Monsanto [12] and Hammond et al.
[14] submitted as evidence for proving the safety of
NK603 maize to suffer from comparable deficiencies.
We did find critical double standards in acceptance and
rigor of the evaluation of feeding studies submitted as
proof of safety for regulatory approval to EFSA. We fur-
ther conclude that during 23 years of EU regulation for
GM organisms and various GM crop risk assessments
and approvals, regulatory sciences and methodology
are used that were developed under the contrasting
US regulatory concept. It is this mismatch between
these different legal frameworks and the choice of risk
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http://www.enveurope.com/content/25/1/33assessment methodology that we see to be the basis of the
often-stated public mistrust in the EU authorities. Only
recently, the EU authorities started to build up an imple-
menting system that takes its directives from the current
EU legislation and is supportive of its own approach. Con-
cerns about the intransparent and arbitrary use of refer-
ence controls as instrument to state biological irrelevance
of significant differences between GM organisms and its
parents must be addressed in these ongoing activities. Ac-
tivities of prime concern in this regard is the GMO Risk
Assessment and Communication of Evidence (GRACE)
Project [65] developing protocols for 90-day rat feeding
trials with GM plants and certainly influencing the sug-
gested development of respective 2-year testing protocols
with rats. But until now, the GRACE Project adheres to
the intransparent use of reference varieties. Until the sci-
entific questions with regard to appropriate risk research
and assessment are resolved and the application of double
standards has ceased, we do not expect that neither the
public nor the scientific debate will subside.
Additional files
Additional file 1: Analysis of 21 long-term toxicity and/or carcino-
genicity studies with SD rats according to selected EFSA criteria.
Additional file 2: Summary of statistically significant differences
between test and controls groups in Monsanto [12].
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